Context Therapeutics LLC

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Context Therapeutics Inc said it closed 2021 with a balance sheet of nearly $50 million. As of December 31, 2021, the women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers said its cash, cash equivalents, and restricted cash were $49.7 million -- compared to $0.3 million at the end of 2020.

Context Therapeutics closes 2021 with balance sheet of nearly $50M

Investor R&D event on April 13 th to highlight new preclinical data to be presented at AACR Annual Meeting

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Edison Investment Research has initiated coverage of Context Therapeutics (NASDAQ:CNTX) Inc with a valuation of $134.9 million or $8.45 per share. The shares are currently trading at $1.81.

Edison Investment Research initiates coverage of Context Therapeutics Inc with valuation of $8.45 per share

If 2021 was a pivotal year for Context Therapeutics (NASDAQ:CNTX) Inc, 2022 promises to be even more so.  Fresh from a US$31.25 million fundraise and last October's debut on the Nasdaq, the clinical-stage biopharmaceutical company focused on bettering the lives of women living with cancer, is developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers.

Context Therapeutics prepares for a busy 2022 as it advances women's oncology treatments

PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will deliver a corporate presentation during the Sachs 15th Annual European Life Sciences CEO Forum taking place virtually March 1-2, 2022.

Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

Flotek Industries

Palisade Bio

Senseonics Holdings

Are these on your list of the best penny stocks to buy right now? Here's what analysts think The post 4 Penny Stocks To Buy Now According To Analysts, Targets Over 300% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy Now According To Analysts, Targets Over 300%

Context Therapeutics Inc is beefing up its research and development team with the appointments of two new executives. Christopher Beck will take on the role of senior vice president of operations and Mark Fletcher will be the firm's new vice president of research and development, according to a statement from the company.

Context Therapeutics adds two new executives to strengthen its research and development team

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D

Context Therapeutics® Strengthens Research & Development Team

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022.

Context Therapeutics® to Participate in Two January 2022 Investor Conferences

Context Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial. The post CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today appeared first on InvestorPlace.

CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today

Context Therapeutics (NASDAQ:CNTX) Inc. said Onapristone extended-release (ONA-XR) has shown significantly increased suppression of tumor cell proliferation in postmenopausal patients with progesterone receptor-positive (PR+) early breast cancer.  The positive data came from the window-of-opportunity clinical trial of ONA-XR and was presented during the 2021 San Antonio Breast Cancer Symposium (SABCS), the company said in a statement.

Context Therapeutics announces positive data from Onapristone extended release in early breast cancer

The stock price of Context Therapeutics Inc (NASDAQ: CNTX) increased by over 30% pre-market today. This is why it happened.

Context Therapeutics Stock (CNTX): Why The Price Surged Today

Context Therapeutics Inc (NASDAQ: CNTX) posted data from the window-of-opportunity trial of onapristone extended-release (ONA-XR) in postmenopausal patients with progesterone receptor-positive (PR+) early breast cancer. The data were presented at San Antonio Breast Cancer Symposium.

Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer

Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Context Therapeutics (NASDAQ:CNTX) Inc said it has completed its previously-announced private placement, raising gross proceeds of about $31.3 million, before deducting offering expenses, by issuing 5 million of its common shares together with 5 million common share purchase warrants. Each share of the offering and accompanying warrant were sold at a combined offering price of $6.25, with the warrants having a five and one-half year term and an exercise price of $6.25 per share.

Context Therapeutics closes its $31.3M private placement

PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women's oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced that it has closed its previously announced private placement for the sale of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,000,000 shares of common stock ("Warrants"), which resulted in gross proceeds to Context Therapeutics of approximately $31.25 million, before deducting offering expenses (the “Offering”). Each share of common stock and accompanying Warrant were sold at a combined offering price of $6.25. The Warrants have a five and one-half year term and an exercise price of $6.25 per share.

Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

Context Therapeutics Inc (NASDAQ:CNTX), a women's oncology company, said it is in a pivotal period following its debut on the Nasdaq and a recent private placement of its units that extends its cash runway into 2024. Releasing third-quarter results, the company told investors it also strengthened its leadership team with the addition of chief financial officer Jennifer Minai-Azary and chief legal officer Alex Levit, who was instrumental in getting Context Therapeutics (NASDAQ:CNTX) listed.

Context Therapeutics reports 3Q results during a “pivotal” period for the company

Entered into $31.25 million Private Placement Agreement

Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

Newly listed Context Therapeutics Inc (NASDAQ: CNTX) has announced a private placement of $31.25 million. The placement includes 5 million shares together with warrants to purchase 5 million shares.

Context Therapeutics Shares Drop After Raising $31M Via Equity

PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women's oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced that it has entered into definitive securities purchase agreements for a private placement with accredited investors of 5,000,000 shares of common stock of Context Therapeutics together with warrants to purchase 5,000,000 shares of common stock (“Warrants”), which will result in gross proceeds to Context Therapeutics of approximately $31.25 million, before deducting placement offering expenses. Each share of common stock and accompanying Warrant are being sold together at a combined offering price of $6.25. The Warrants have a five and one-half year term and an exercise price of $6.25 per share. This private placement is expected to close on December 6, 2021, subject to customary closing conditions.

Context Therapeutics Inc. Announces $31.25 Million Private Placement

Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer

Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Context Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications.

Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential

Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO

Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer

Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Estrogen Receptor Antagonist to Determine Potential of Complete Hormone Blockade on Metastatic Breast Cancer Outcomes Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Estrogen Receptor Antagonist to Determine Potential of Complete Hormone Blockade on Metastatic Breast Cancer Outcomes

News for Context Therapeutics LLC Stock (CNTX)